Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience

Background Effective treatment options for advanced pancreatic cancer are finite. NAPOLI-1, a phase III randomized trial, demonstrated the efficacy of nanoliposomal irinotecan with fluorouracil/leucovorin (nal-IRI + 5-FU/LV) for the treatment of advanced pancreatic cancer following progression on ge...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	BMC cancer Ročník 18; číslo 1; s. 693 - 10
Hlavní autoři:	Glassman, Danielle C., Palmaira, Randze L., Covington, Christina M., Desai, Avni M., Ku, Geoffrey Y., Li, Jia, Harding, James J., Varghese, Anna M., O’Reilly, Eileen M., Yu, Kenneth H.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London BioMed Central 27.06.2018 BioMed Central Ltd Springer Nature B.V BMC
Témata:	5-Fluorouracil Adult Aged Aged, 80 and over Analysis Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomedical and Life Sciences Biomedicine Cancer Cancer Research Cancer therapies Chemotherapy Development and progression Dosage and administration Drug delivery systems Drug therapy Drugs FDA approval Female Fluorouracil Fluorouracil - administration & dosage Genomics Health Promotion and Disease Prevention Humans Irinotecan Irinotecan - administration & dosage Irinotecan - adverse effects Liposomes Male Medical and radiation oncology Medical diagnosis Medical prognosis Medical records Medicine/Public Health Metastasis Middle Aged MM-398 Mutation Nal-IRI Nanoliposomal irinotecan Nanoparticles Oncology Pancreatic cancer Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - mortality Patients Proto-Oncogene Proteins p21(ras) - genetics Research Article Retrospective Studies Surgical Oncology Vehicles 5-fluorouracil Nanoliposomal irinotecan MM-398 Pancreatic cancer Nal-IRI
ISSN:	1471-2407, 1471-2407
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!